Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX)‘s stock had its “sector perform” rating restated by equities research analysts at Royal Bank Of Canada in a research note issued to investors on Monday. They currently have a C$39.00 price target on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s price objective suggests a potential upside of 69.20% from the company’s previous close.

Other equities analysts have also recently issued research reports about the stock. Scotiabank decreased their target price on shares of Valeant Pharmaceuticals Intl from C$32.00 to C$17.00 and set a “sector perform” rating on the stock in a research report on Wednesday, November 9th. TD Securities decreased their target price on shares of Valeant Pharmaceuticals Intl from C$38.50 to C$18.00 and set a “hold” rating on the stock in a research report on Thursday, November 10th.

Valeant Pharmaceuticals Intl (TSE:VRX) opened at 23.05 on Monday. The company’s market cap is $8.01 billion. The stock’s 50 day moving average is $26.29 and its 200-day moving average is $31.45. Valeant Pharmaceuticals Intl has a 52-week low of $18.41 and a 52-week high of $165.77.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this report on another domain, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2016/11/30/royal-bank-of-canada-reiterates-sector-perform-rating-for-valeant-pharmaceuticals-intl-inc-vrx-2.html.

Valeant Pharmaceuticals Intl Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Stock Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related stocks with our FREE daily email newsletter.